Third-quarter adjusted EPS of $4.69 beat the ~$4.12–$4.14 consensus and full-year guidance moved up to at least $20.50 — yet revenue is shrinking (−0.4%) because UnitedHealth is deliberately shedding Medicare Advantage lives. The market has already re-rated the recovery from ~14x to ~20x earnings. Is 2026’s margin repair a durable base to compound from, or a harvest that is already in the price? Six analyst lenses, three scenarios, four time horizons.
Gray line = UNH’s actual path from its Nov ’24 high ($631) through the Aug 1 ’25 close low ($235), the Mar 27 ’26 52-week low ($256) and the Jul 16 ’26 high ($462) to $417.00 today; it is built only from dated, sourced closes (no invented intermediate months), so the window is 23 months, not a full 24. Colored paths = synthesized scenario midpoints forward (price = same-year adjusted EPS × exit multiple), probability-weighted bear 30% · base 45% · bull 25% — tilted to the bear side because a DOJ probe and a policy-funding gap are unresolved. Open circle = Street 12-month consensus $477 (26 analysts, range $380–$529). Axis starts at $200, not zero.
Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.
The same Q3 print supports a $315 or a $490 stock depending on which framework you trust. Each lens below is a synthesized expert perspective with its own 12-month target. Panel mean: $433 (+4%) vs. a $477 Street consensus.
Earnings power is rebasing up from a $20.50 floor. Q3 adjusted EPS grew 61%, Optum Health earned $735M vs $41M, and management called the low end of its 13–16% growth target a “reasonable starting point” for 2027 — above where consensus sits. Medicare Advantage margins are tracking the top of the 2–4% range.
$22.8B of trailing free cash flow is a ~6.1% yield on a $374B market cap, with $8.2B of dividends paid over the last twelve months and $5.0B of buybacks year-to-date. Debt-to-capital is 41.7% and heading toward 40%. The floor is cash, not hope — but ~$5.8B of the cash flow came from growth in claims reserves, which is timing.
The repair was bought with scale: revenue −0.4%, Optum Health revenue −10%, plan exits that touch roughly 1M seniors across UnitedHealth and Humana, and a drop in members in 4-star-plus plans from 81% to 68%. DOJ civil and criminal probes remain open, and Optum Health guides to a “meaningfully negative” Q4. A re-rated 20x multiple leaves no room for a stumble.
No peer pairs 48.3M insured members with a pharmacy-benefit arm where more than half of covered lives are now external, retention is in the high 90s, and specialty volumes grew 2.6% while overall volumes fell 5%. Optum Health reaches ~20M patients, ~4M in fully accountable relationships. The moat is the stack; the risk is that its profits depend on government payment rules.
Price sits above both the 50-day ($387.80) and 200-day ($360.27) averages, with RSI near 69 — strong, bordering on stretched. The stock is 63% off its March low but ~10% below the July high ($461.62), and 20.3x current-year EPS is mid-range against 17.4x–24.2x at the year-ends of 2021–25. A retest of the July high is the technical base case; a close above it opens the path.
CMS finalized a 2.48% Medicare Advantage rate rise for 2027 (vs. 0.09% proposed) — a relief, but insurers still cite a gap versus medical cost trend. Government projections see ~34M MA enrollees, ~6% fewer than today, and management calls 2026 a trough year for Medicaid margins. A hot September CPI and a ~5.2% 10-year argue against multiple expansion even as healthcare draws defensive flows.
What the sell-side expects over the next year. Bars are sorted low to high; the dashed line is today’s $417.00 — eight of the nine targets shown sit above it; only TD Cowen’s Hold ($402) sits below.
Sell-side 12-month targets — nine of the 26 analysts S&P Global polls (via StockAnalysis/TipRanks, Oct 9–21, 2026). Consensus mean $477.04, median $490; 22 of 26 rate the stock Buy or Strong Buy, 4 Hold, none Sell. Targets cluster tightly ($402–$526, eight of nine Buy) even after the stock’s 63% rebound, and several desks trimmed (Bernstein $512→$500, Raymond James $475→$450) while others raised (RBC $478→$498, J.P. Morgan $516→$524) after the Oct 13 print. The Street is at +14%; our blended 1-year view is roughly flat.
Synthesized scenario midpoints (mid-year). Returns shown vs. today’s $417.00. These are illustrative frameworks, not forecasts — the outcome hinges on whether 2027 earnings arrive and whether Medicare Advantage margins hold once the plan exits are behind it.
Where the money actually goes. At $450B of revenue, plotting revenue would flatten every other bar, so operating cash flow stands in for it. The bull and bear theses both live in the gap between these four bars.
Cash flow fell from $29.1B (2023) to $19.7B (2025) as medical costs ran hot, then rebounded to $26.2B over the twelve months to September 2026; free cash flow went $25.7B → $16.1B → $22.8B. Capex is steady at ~$3.4–3.6B, so the swing is all operating. The bear’s caveat: ~$5.8B of the trailing figure is growth in unpaid-claims reserves (cash held for bills not yet paid), so it is partly timing. Total debt peaked at $83.0B at year-end 2025 and is $74.3B now — about 3.3 years of free cash flow — with debt-to-capital at 41.7%. Revenue for reference: $371.6B (2023), $400.3B (2024), $448.0B (2025), ~$448.7B consensus for 2026. Valuation snapshot (Oct 21): EV/EBITDA 14.6x, P/S 0.83x, P/FCF 16.4x, PEG 1.29. Source: S&P Global Market Intelligence via StockAnalysis; the company’s Q3 release.
Each scenario price is an EPS estimate times an exit multiple. This is the earnings ladder the base case is built on — note it is still below the 2024 peak even in 2027.
Adjusted (non-GAAP) EPS: $27.66 (2024) and $16.35 (2025) reported; $20.51 (2026E) and $23.23 (2027E) are Street consensus, with 2026 management guidance “at least $20.50.” The lighter 2028E–2031E bars are our base-case extrapolation at +12%/yr — not consensus. Base-case 2031 EPS of ~$36.6 at ~17.5x ≈ the $640 five-year target. Valuation: 20.3x 2026E adjusted EPS (18.4x next-twelve-months; 23.8x trailing GAAP), versus 17.4x–24.2x at the year-ends of 2021–25. Peers on forward earnings: Cigna ~8.3x and CVS ~10.7x (Yahoo, Oct 14); Humana ~24.9x on normalized earnings (Morningstar, Oct 20) — so UNH trades at a premium to the insurers and in line with the other Medicare-recovery story. One aggregator shows 2024 adjusted EPS at $27.14; we use $27.66, which two sources agree on.
Q3 FY26, year-over-year. Read the revenue lines against the profit lines: that disconnect is the whole thesis — and the whole debate.
Revenue lines (olive, plus Optum Rx earnings) are steady-to-shrinking: consolidated revenue $112.7B vs $113.2B, UnitedHealthcare $86.3B vs $87.1B, Optum Health $22.9B (−10%, fewer value-based patients in some markets). The profit lines (clay) are rebounding off a depressed Q3 2025: earnings from operations $6.6B vs $4.3B, UnitedHealthcare $2.8B vs $1.8B, adjusted EPS $4.69 vs $2.92. Optum Health operating earnings of $735M vs $41M (+1,693%, bar truncated at the axis break) come off a near-zero base — the percentage is arithmetic, the direction is the point. Sources: company Q3 2026 release (Oct 13) and call.
The entire valuation argument compresses into one disagreement: is the 2026 margin repair the new base, or the high-water mark of a harvest?
Where each risk sits over the next 3–5 years, not just how big it is. The hot upper-right corner — likely and high-impact — is the one that matters; most of UnitedHealth’s legal and structural risks sit one row down, in “possible.” Placements are our judgment.
Medical cost trend outruns Medicare and Medicaid payment rates again; the 88.4% medical care ratio slips back toward 90% and the $20.50 floor stops being a floor.
Members in 4-star-plus plans fall from 81% to 68% for 2027; fewer quality-bonus dollars arrive in 2028 payments even as margins improve.
Management guides a “meaningfully negative” Optum Health Q4 and multi-year Optum Insight investment; the Optum recovery arrives later than the headline implies.
Civil and criminal probes into Medicare billing conclude with penalties or forced changes to risk-adjustment practices in the company’s largest revenue stream.
Federal drug-pricing or rebate rules compress Optum Rx, which earned $1.7B of operating profit in Q3 alone.
A repeat of the 2024 Change Healthcare-style attack disrupts claims flow across the network — low odds, but it reprices the stock and invites regulation.
A structural change to Medicare Advantage risk adjustment or benchmarks resets the economics of the segment that produces the most revenue.
Hot inflation and a ~5.2% 10-year pull the multiple from 20x toward the mid-teens even if earnings deliver.
State funding stays uneven and 2026 proves not to be the trough; Medicaid margins stay below the rate-adequate level management expects by 2028.
Hover the dotted terms in the metrics, or scan the desk’s working definitions here.